Mersana Therapeutics, Inc. Quarterly Debt-to-equity in % from Q2 2019 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Mersana Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q2 2019 to Q3 2024.
  • Mersana Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 940 %, a 209% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 940 +636 +209% Sep 30, 2024
Q2 2024 590 +317 +116% Jun 30, 2024
Q1 2024 383 +168 +78.2% Mar 31, 2024
Q4 2023 351 +197 +128% Dec 31, 2023
Q3 2023 304 +192 +171% Sep 30, 2023
Q2 2023 274 +204 +295% Jun 30, 2023
Q1 2023 215 +162 +309% Mar 31, 2023
Q4 2022 154 +116 +305% Dec 31, 2022
Q3 2022 112 +84.3 +304% Sep 30, 2022
Q2 2022 69.3 +47.6 +219% Jun 30, 2022
Q1 2022 52.6 +34.8 +196% Mar 31, 2022
Q4 2021 38 +19.4 +104% Dec 31, 2021
Q3 2021 27.7 +7.42 +36.5% Sep 30, 2021
Q2 2021 21.8 -3.36 -13.4% Jun 30, 2021
Q1 2021 17.7 -17.7 -49.9% Mar 31, 2021
Q4 2020 18.6 -9.66 -34.2% Dec 31, 2020
Q3 2020 20.3 -25.9 -56% Sep 30, 2020
Q2 2020 25.1 -45.1 -64.2% Jun 30, 2020
Q1 2020 35.4 Mar 31, 2020
Q4 2019 28.2 Dec 31, 2019
Q3 2019 46.2 Sep 30, 2019
Q2 2019 70.2 Jun 30, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.